![]() |
Technical Data |
|
C2099-64 |
CCL27, aa25-112, Recombinant, Human (C-C Motif Chemokine 27, Chemokine (C-C Motif) Ligand 27, ALP, CC Chemokine ILC, Cutaneous T-cell-attracting Chemokine, CTACK, CTAK, ESkine, IL-11 R-alpha-locus Chemokine, ILC, PESKY, Skinkine, Small-inducible Cytokine |
100ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Cutaneous T cell-attracting chemokine CCL27 is a member of the chemokine superfamily and the subfamily of r C-C chemokines that binds chemokine receptor CCR10. Chemokines are a superfamily of small secreted proteins that attract their targets by interacting with G protein-coupled receptors expressed on the migrating cell. CCL27 is involved in the preferential migration and recruitment of cutaneous lymphocyte-associated antigen CLA+ memory lymphocytes. Recombinant human CCL27 protein was expressed in E. coli. Source: Recombinant corresponding to aa25-112 of human CCL27 expressed in E. coli. AA Sequence: MFLLPPSTAC CTQLYRKPLS DKLLRKVIQV ELQEADGDCH LQAFVLHLAQ RSICIHPQNP SLSQWFEHQE RKLHGTLPKL NFGMLRKMG Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Molecular Weight: 10.3kD |
Source: E. coli Purity: ~ 95% (SDS-PAGE). Purified by using conventional chromatography techniques. Concentration: As reported Form: Supplied as a liquid in 10mM Sodium Citrate, pH 3.5, 10% Glycerol. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Homey B., et al. (2002) Nat Med. 8(2):157-65. 2. Kanda N., et al. (2007) Clin Exp Allergy. 37(7):1074-82.
|
||